Scientific Advisory Committee

The Scientific Advisory Committee (SAC) consists of a core of members representing the major disciplines relevant to ANZUP, nominated and appointed upon the recommendation of those groups. In addition, chairs of the SAC subcommittees are members of the SAC by virtue of their appointment as Chair. The SAC meets by teleconference quarterly with the intention of meeting face-to-face at least once per year.


Ian Davis

Chair

Professor Ian Davis MB BS PhD FRACP FAChPM is a medical oncologist, cancer immunologist and clinician-scientist. He is Professor of Medicine, Monash University and Eastern Health, and Head of the Eastern Health Clinical School (EHCS), where he is responsible for all clinical research within Eastern Health through the Monash Eastern Clinical Research Unit (ECRU). He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, and is an adjunct Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. He heads the Uro-oncology Laboratory at EHCS in which basic and translational research occurs in prostate cancer, and leads the Eastern Health genitourinary cancer clinical trial program. He is the founder of the Urologic Oncology Group of the Clinical Oncology Society of Australia (COSA), member of COSA Council, and previously COSA Board director. He is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP), and chair of the ANZUP Board and of its Scientific Advisory Committee.

Martin Stockler

Deputy Chair

Martin Stockler is co-director of Oncology at the NHMRC Clinical Trials Centre and its Clinical Lead for ANZUP. He is Professor of Oncology and Clinical Epidemiology at the University of Sydney, and a consultant medical oncologist at the Concord Repatriation General Hospital and at the Chris O’Brien Lifehouse RPA. Research interests include: the design, execution, analysis and synthesis of cancer clinical trials; the assessment of quality of life and patients’ preferences; evidence-based medicine in clinical practice and medical education; patient-doctor communication; prognostication; and, the management of genitourinary, lung, gynaecologic, and advanced cancers. The aim of Martin’s research has been to improve survival time, quality of life, prognostication, communication and decision-making for people affected by cancer. Research highlights include pivotal studies establishing the benefits of: chemotherapy and targeted drugs for cancers of the prostate, testis, kidney, lung, breast and ovary; presenting information about prognosis as best, worst and typical scenarios for survival time; and, preference studies documenting the benefits patients judge necessary to make adjuvant therapy worthwhile in breast, lung, colorectal, endometrial, and kidney cancers.


Arun Azad

A/Prof Arun Azad is a medical oncologist and translational researcher focusing on genitourinary malignancies. After completing his medical oncology training and a cell biology PhD, Arun moved to the British Columbia (BC) Cancer Agency, Vancouver, Canada in 2013 for a 2-year fellowship. At BC Cancer Agency, his major laboratory project centered on genomic profiling of circulating cell-free DNA in advanced prostate cancer patients developing resistance to next-generation hormonal agents which led to 4 highly prestigious Merit Awards from the American Society of Clinical Oncology. Overall, Arun’s clinical and research activities have resulted in over 60 publications, a patent, 11 oral presentations at national and international meetings, Poster Highlights Sessions at the 2014 and 2015 ASCO Annual Meeting, 25 competitive prizes and grants and over $4.5M in named funding. In November 2015, Arun returned to Australia to take up appointments at Monash University and Monash Health, where he is leading a translational prostate cancer research program.

Nick Buchan

Dr Nick Buchan is a Urologist based in Christchurch, New Zealand and works in both public and private practice. Nicks practice focuses on the diagnosis and management of urological cancers. Nick gained his experience in medical trials while on fellowship at the Vancouver Prostate Centre. The Vancouver Prostate Centre is one of the largest research and clinical centres in the world that focuses on translational research into prostatic diseases, prostate cancer in particular. Currently Nick is director of the Canterbury Urology Research Trust (CURT). CURT is a trust that conducts urological trials for CROs as well as its own investigator lead trials in urological conditions with the main focus being urological oncology. Nick is also a director of a privately owned hospital in Christchurch, Forte Health and large Urology specialist practice, Urology Associates.

Suzanne Chambers 

Professor Suzanne Chambers is a registered nurse and health psychologist who has worked as a practitioner researcher in psychosocial support for people with cancer for over 20 years. Her current role is Menzies Foundation Professor of Allied Health Research at the Menzies Health Institute Queensland (MHIQ) at Griffith University and before this she was the Director of Research at Cancer Council Queensland. She has worked closely with prostate cancer support groups since the late 1990s and Chairs the Quality of Life and Supportive Care Committee for the Australia and New Zealand UroGenital and Prostate Cancer Trials Group. Professor Chambers has published extensively on the psychological aspects of cancer and has a specific research focus on prostate cancer survivorship.

Warick Delprado 

Prof. Warick Delprado is the Director of Histopathology (tissue pathology) at Douglass Hanly Moir Pathology in Sydney. He is a Fellow of the International Society of Urological Pathology and has served on the Society’s consensus review committees on Gleason Grading and Prostate Pathology. He has a major interest in genitourinary pathology and cytology, and has published and co-authored many papers in the area, as well as presenting many speaking engagements.

Haryana Dhillon

Dr Haryana Dhillon, Research Fellow in Cancer Survivorship at the Centre for Medical Psychology and Evidence-based Decision-making (CeMPED), School of Psychology, University of Sydney. Chair of the Clinical Oncological Society of Australia (COSA) Survivorship Group, a member of COSA Board Committee and Council. With the COSA Survivorship Group Haryana has been leading work developing an Astralian model of survivorship care. Haryana co-leads the survivorship research group with active research projects in physical activity, cognitive function, and supportive care after a cancer diagnosis. She is a chief investigator on a number of projects investigating health literacy, informed decision-making, and patient education. Haryana has made a major contribution to the development of several of Australasia’s Cancer Cooperative Trials Groups in the past and is committed to investigator-initiated research that addresses questions of importance to patients, caregivers, and health professionals.

Joe Esposito 

Mr Joe Esposito is a Melbourne director who owns a BOQ (Bank of Queensland) Owner - Manager Bank branch in the inner Melbourne city suburb of Collingwood. Prior to this was a management consultant and had over 20 years in corporate banking in Australia and New Zealand. He was also CEO of ASX listed Jetset Travelworld Limited between 2003 and 2006. Mr Esposito has a close affinity with the objectives of ANZUP and the needs of consumers. He has Bachelor of Commerce and Master of Applied Finance degrees. He is a graduate member of the Australian Institute of Company Directors.
 

Craig Gedye

Dr Craig Gedye is a physician/scientist, dual trained as a medical oncologist and as a basic science cancer researcher. He is inspired by working for patients with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle, to do clinical, translation and basic cancer research at the University of Newcastle, Hunter Medical Research Institute. Craig’s research focuses on complexity in cancer, with a particular interest in understanding "intratumoural heterogeneity". In every patient, every cancer cell is a bit different to every other cancer cell. Some cancer cells seem to be able to spread and cause trouble; others are less aggressive. What determines these differences? Can we exploit them to target cancer cells that are behaving differently? Projects currently include identification and isolation of circulating tumour cells in glioblastoma, repurposing drug screening in renal cell carcinoma, growth factor and alternate anigiogenic factor pathway analysis in renal cell carcinoma and pre-analytical analysis of immunotherapy markers. Clinical trial activity includes a number of industry trials and ongoing development of investigator-initiated studies in glioblastoma, renal cell carcinoma and prostate cancer.


Fritha Hanning 

Fritha was born in Auckland and is a graduate of Auckland Medical School, having studied at Otago University for her preclinical medical years. During her advanced training she worked extensively in the United Kingdom at the Royal London and St Bartholomew's hospitals, the Royal Free Hospital London, and at Cancer Research UK in Oxford. While in the United Kingdom she completed a certificate in palliative care and symptom management from the University of Wales.Although her main focus is genitourinary cancer, Fritha treats patients with a number of different cancers including gastrointestinal. Fritha has dual appointments, in addition to her role at Auckland City Hospital, she is a director of Canopy Cancer Care, and an Honorary Lecturer at the university of Auckland medical school. Fritha is the chairperson and initiator of the Genitourinary Special Interest Group for New Zealand. She is a key contributor to on-going scientific research in genitourinary cancer, with involvement in current trials and as a New Zealand representative on the Australia New Zealand Urogenital and Prostate Cancer scientific committee.

Dickon Hayne

Professor Dickon Hayne is a clinical academic who leads the urological research team within the in the School of Surgery and is responsible for undergraduate education in urology at the University of Western Australia. He works as consultant urological surgeon and is the Head of Urology at Fiona Stanley Hospital, WA. He is Chair of the Bladder Cancer Sub-committee of the Australian & New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP), is an SAC member and is widely engaged in other sub-committees and activities of ANZUP. He is lead clinician for the Urological Tumour Collaborative of the WA Cancer and Palliative care Network (WACPCN) and is the inaugural chair of the charitable research group, the West Australian Urologic Research Organisation. His major clinical and research interests are urological cancer, in particular bladder cancer.
 

George Hruby

A/Prof George Hruby completed a fellowship at the Royal Prince Alfred Hospital in 1999 and was awarded a clinical fellowship at the University of Toronto.  He spent 13 months in Toronto at a high volume academic centre focused on genito-urinary cancers. In Dec 2000 he commenced as Staff Specialist in Radiation Oncology at the Royal Prince Alfred Hospital, (now Lifehouse). Clinical milestones have included the establishment of the High Dose Rate brachytherapy program at Royal Prince Alfred Hospital with over 300 implants performed since inception in 2002. Whilst at RPA, George was instrumental in leading the introduction of more sophisticated techniques for the treatment of prostate cancer such as image guided radiation treatment (IGRT) in 2007, IMRT (intensity modulated radiation treatment) for anal cancer  in 2009, and for prostate cancer in 2010.  In 2014 the first prostate cancer patients were treated with SABR (stereotactic ablative body radiotherapy) for oligo-metastatic disease. He has mentored and taught radiation oncology registrars as well as medical students, presented at many scientific meetings and co-authored over 75 peer reviewed publications. He currently works at Royal North Shore Hospital. 

Belinda Jago

Belinda has worked predominantly in the human resources field after completing a Bach of Business in 1981. She had 12 years with ANZ where she held a variety of operational and strategic HR roles. After a short career break Belinda returned to work in 1999 in various HR management roles within the Finance and IT sector. Currently Belinda is the HR Director at Active Display Group, a national manufacturing business specialising in point of sale material. She joined the group in 2004 with a special interest in acquisitions and restructuring. Belinda’s interest in ANZUP stems from her role as a carer for her daughter who was diagnosed with kidney cancer in 2006 at the early age of 13. Volunteering with ANZUP is an opportunity for Belinda to share the knowledge and skills she has acquired during her own experience and to pursue her passion for assisting cancer patients, their carer’s and families with a particular interest in kidney and AYA cancers.
 

James Kench

Professor James Kench is Director of the Department of Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, a Clinical Professor of the University of Sydney, and the senior Visiting Pathologist at the Kinghorn Cancer Centre/Garvan Institute of Medical Research. He has internationally recognized expertise in prostate cancer pathology and a major research interest in diagnostic and prognostic biomarkers.He has published over 130 peer reviewed journal articles and is a member of key international and Australasian committees relating to prostate cancer, including the International Collaboration on Cancer Reporting (ICCR) Dataset Steering Committee and the International Society of Urological Pathology (ISUP) Council. In addition, Dr Kench co-chairs the ICCR Prostate Cancer Dataset Authoring Committee and chairs the National Structured Pathology Reporting Project.
 

Andrew Martin 

Andrew James Martin (PhD) is Senior Lecturer in Biostatistics at the NHMRC Clinical Trials Centre University of Sydney. Andrew has over 15 years experience in clinical trials research gained from senior roles within research-based pharmaceutical organisations and the University of Sydney. His specific interest is in the application of optimal study designs and analysis methods to the development and evaluation of health interventions. He is responsible for the provision of statistical leadership to clinical trial networks in a variety of disease areas to design, undertake, analyse and report on clinical trials.

Margaret McJannett

Ex-officio

Ms Margaret McJannett is the Chief Executive Officer (CEO) for ANZUP Cancer Trials Group Ltd. Her professional background is in nursing with a post-graduate certificate in oncology nursing. Margaret worked as a clinical nurse consultant at The Sydney Melanoma Unit, research coordinator in the Medical Psychology Research Unit, Sydney University and project officer at the Queensland Institute of Medical Research in Brisbane.Ms McJannett more recently was the EO of the Clinical Oncological Society of Australia (COSA) and Cancer Council Australia before taking up her role with ANZUP. She has facilitated and contributed to COSA's and CCA's expert committees, the national Cancer Co-operative Clinical Trials Groups and COSA's collaborative role with key stakeholders including other NGO's Cancer Voices, Government agencies and Industry partners. 

 

Pamela Russell 

Prof Pamela J Russell, AM, PhD, Professor, Head of Biomedical Imaging and Prostate Cancer Models Medicine, Australian Prostate Cancer Research Centre - Qld, and member of Institute of Health and Biomedical Innovation, Queensland University of Technology, is a cancer biologist and immunologist who has been the Director of the Oncology Research Centre in the Prince of Wales Clinical School at the University of New South Wales. She helped to initiate and was an inaugural director of the Prostate Cancer Foundation of Australia, of which she has been made a life member. She was awarded an AM for her contributions to prostate and bladder cancer research in 2003. She was given life membership to the Australasian Gene Therapy Society in 2009, awarded "Outstanding Prostate Cancer Researcher of the year" in 2010 by the PCFA and represented Australasia on the scientific committee of the Global Action Plan for Movember (202-14).In 2015 she became a Fellow of the Australian Academy for Health and Medical Science, received the Women in Technology Life Sciences Outstanding Achievement Award and the University of Canberra Alumni Excellence Award in Health.

Kathryn Schubach

Kath Schubach has a masters in Nursing Science and postgraduate qualifications in oncology nursing. She works as a Nurse Practitioner within the urology service and is also a clinical research nurse with the department of cancer experiences at Peter Mac Callum Cancer Centre (Peter Mac). Her main interests are in prostate, bladder and testis cancer, particularly patients sexual health concerns following cancer treatments. She is currently Chairperson of the Victorian Urological Nurses Society (VUNS) and also the Chair of the Australian and New Zealand Urology Nurses (ANZUNS) Uro-Oncology Special Interest Group.

Shomik Sengupta 

Shomik Sengupta is a consultant urologist and Director of Research & Training at Austin Health, and Clinical Associate Professor at the Department of Surgery (Austin) of Melbourne University. Shomik has a practice with a uro-oncology subspecialty interest – including open, laparoscopic and robotic cancer surgery. He is currently the chair of the Victorian training committee and leader of the GU Oncology advisory group within USANZ. Shomik also has a strong interest in urologic research, including involvement in clinical trials through the ANZUP trials group. He has completed a Masters in Surgery (2002) and a Doctorate in Medicine (2014) through the University of Melbourne and has more than 70 original publications to date.

Chris Sweeney 

Dr. Christopher J Sweeney received his medical degree from the University of Adelaide, South Australia in 1993 and went on to complete a fellowship in Haematology/Oncology at Indiana University Medical Center. He became a faculty member at Indiana University and was appointed Associate Director for Clinical Research for the Simon Cancer Center. In 2008 he was granted appointments at the Royal Adelaide Hospital and University of Adelaide and then joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute with an appointment at Harvard Medical School. He is a member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, and the American Association for Cancer Research. His primary research interest is biomarker drug discovery and development. His academic focus is management of genitourinary malignancies. He has served on the Editorial Board for ASCO’s “Journal of Clinical Oncology” and the Program and Cancer Education Committees of the American Society of Clinical Oncology and ASCO GU. He receives peer reviewed funding from the National Institutes of Health and the Department of Defence. 

Bertrand Tombal

Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. Professor Tombal is a member of the Royal Academy of Medicine of Belgium. He is the current chairman of the Clinical Trial Division of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also a member of the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology.


Guy Toner 

Associate Professor Guy Toner is a Consultant Medical Oncologist at Peter MacCallum Cancer Centre and Associate Professor of Medicine at the University of Melbourne. He is a graduate of the University of Melbourne and undertook sub-specialty training in medical oncology in Melbourne before spending 3 years at Memorial Sloan-Kettering Cancer Centre, New York. His clinical and research interests include all urological cancers with a particular interest in testicular cancer, which was the subject of his MD thesis. He has been an active member of other cooperative trials groups including as a past member of the Scientific Advisory Boards of the ANZ Breast Cancer Trials Group and the Australian Sarcoma Study Group. He was Head of the Medical Oncology Unit at Peter MacCallum Cancer Centre from 1993-2007. He was Chair of the ANZ Germ Cell Trials Group from 1995 until it merged to form ANZUP and since then he has been the Deputy Chair of ANZUP.

Ben Tran 

Ben Tran is a consultant Medical Oncologist based at Peter MacCallum Cancer Centre. He also holds a Clinician Scientist appointment at the Walter and Eliza Hall Institute. Clinically, his focus lies entirely within the genitourinary (GU) tumour stream, in particular, testicular and urothelial cancers. Following his medical oncology training in Australia, Ben completed an overseas Fellowship in Drug Development and Urological cancers at Princess Margaret Cancer Centre in Toronto, Canada. There he gained extensive experience in treating GU cancers, conducting Phase I clinical trials, implementing a large scale molecular profiling program and managing large multi-centre databases containing real world patient data. These experiences have allowed him to establish a burgeoning career in Australia, in GU cancers, Early Drug Development and RWD. Ben currently leads the GU clinical trials program at Peter MacCallum Cancer Centre and is Chair of the GU Tumour Group within Cancer Trials Australia, and Chair of the ANZUP Germ Cell Subcommittee.  

Scott Williams 

Scott Williams is a consultant Radiation Oncologist and Associate Professor with the Peter MacCallum Cancer Centre Uro-Oncology service in Melbourne where he has a special interest practice made up almost exclusively of prostate cancer patients. Scott is the chair of the prostate subcommittee of ANZUP. He is heavily involved in research, managing several national and international randomised trials in prostate cancer and is a member of PeterMac ethics as well as several national research and advisory committees. He holds a USA prostate cancer foundation creativity award, their highest individual honour for innovative research ideas. This award relates to novel translational research, while he is also a collaborator on active research grants for work ranging from clinical trials to functional imaging to mathematical modelling to genetics, with national and international collaborations.
© ANZUP 2018. All rights reserved.